用于成人代谢功能障碍相关脂肪性肝病的胆汁酸
Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.
作者信息
Ashmawy Rehab E, Blyuss Oleg, Nikolova Dimitrinka, Pavlov Chavdar S, Gluud Christian, Andrenacci Paola J
机构信息
Faculty of Medicine, Helwan University, Cairo, Egypt.
Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
出版信息
Cochrane Database Syst Rev. 2025 Sep 2;9(9):CD014850. doi: 10.1002/14651858.CD014850.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of oral bile acid-based therapies versus no intervention or placebo, or versus a different bile acid-based therapy, at any dose or regimen, in adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估在任何剂量或治疗方案下，口服胆汁酸类疗法与不干预或安慰剂相比，或与不同的胆汁酸类疗法相比，对诊断为代谢功能障碍相关脂肪性肝病（MASLD）的成年人的益处和危害。
相似文献
1
Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.用于成人代谢功能障碍相关脂肪性肝病的胆汁酸
Cochrane Database Syst Rev. 2025 Sep 2;9(9):CD014850. doi: 10.1002/14651858.CD014850.
2
Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis.用于非酒精性脂肪性肝病和/或脂肪性肝炎的胆汁酸。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD005160. doi: 10.1002/14651858.CD005160.pub2.
3
Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.水飞蓟素用于患有代谢功能障碍相关脂肪性肝病的成年人。
Cochrane Database Syst Rev. 2025 Jun 24;6(6):CD015524. doi: 10.1002/14651858.CD015524.pub2.
4
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.原发性胆汁性胆管炎的药物干预：一项网状Meta分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011648. doi: 10.1002/14651858.CD011648.pub2.
5
Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.代谢功能障碍相关脂肪性肝病中循环胆汁酸的变化：系统评价和荟萃分析。
Biomolecules. 2023 Sep 6;13(9):1356. doi: 10.3390/biom13091356.
6
Vitamin E for people with non-alcoholic fatty liver disease.维生素 E 治疗非酒精性脂肪性肝病。
Cochrane Database Syst Rev. 2024 Oct 16;10(10):CD015033. doi: 10.1002/14651858.CD015033.pub2.
7
Ursodeoxycholic acid for primary biliary cirrhosis.熊去氧胆酸用于原发性胆汁性肝硬化。
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD000551. doi: 10.1002/14651858.CD000551.pub3.
8
Bile acids for liver-transplanted patients.用于肝移植患者的胆汁酸
Cochrane Database Syst Rev. 2010 Mar 17(3):CD005442. doi: 10.1002/14651858.CD005442.pub2.
9
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.非酒精性脂肪性肝病（NAFLD）的药物干预：一项网状Meta分析尝试
Cochrane Database Syst Rev. 2017 Mar 30;3(3):CD011640. doi: 10.1002/14651858.CD011640.pub2.
10
Bile acids for viral hepatitis.用于治疗病毒性肝炎的胆汁酸
Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD003181. doi: 10.1002/14651858.CD003181.pub2.
本文引用的文献
1
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
2
Effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.维生素 A 补充剂用于一级或二级预防对临床重要结局的影响：系统评价随机临床试验的荟萃分析和试验序贯分析。
BMJ Open. 2024 May 30;14(5):e078053. doi: 10.1136/bmjopen-2023-078053.
3
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.代谢相关脂肪性肝病：新命名对美国肝病研究学会非酒精性脂肪性肝病实践指南的影响及更新。
Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9.
4
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.代谢功能障碍相关脂肪性肝病（MASLD）：最新综述
J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
5
Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis.熊去氧胆酸通过调节肠-肝轴缓解非酒精性脂肪性肝病。
Cell Metab. 2023 Oct 3;35(10):1752-1766.e8. doi: 10.1016/j.cmet.2023.07.011. Epub 2023 Aug 16.
6
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
7
Changing epidemiology, global trends and implications for outcomes of NAFLD.非酒精性脂肪性肝病的流行病学变化、全球趋势及其对结局的影响。
J Hepatol. 2023 Sep;79(3):842-852. doi: 10.1016/j.jhep.2023.04.036. Epub 2023 May 9.
8
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
9
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
10
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.代谢相关脂肪性肝病与心血管风险及疾病预防。
Cardiovasc Diabetol. 2022 Dec 3;21(1):270. doi: 10.1186/s12933-022-01697-0.
Zotero 插件